Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study

CONCLUSION: In this study of patients with AF and VHD, patients receiving apixaban had a lower risk for ischemic stroke or systemic embolism and for bleeding when compared with those receiving rivaroxaban.PRIMARY FUNDING SOURCE: National Institutes of Health.PMID:36252244 | DOI:10.7326/M22-0318

Source: Annals of Internal Medicine - October 17, 2022 Category: Internal Medicine Authors: Ghadeer K Dawwas Adam Cuker Geoffrey D Barnes James D Lewis Sean Hennessy Source Type: research